IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

:

Peter HEROLD et al.

Mail Stop: PCT

Serial No. 10/574,108

Attorney Docket No. 2006 0446A

Filed March 31, 2006

.

ORGANIC COMPOUNDS

[Corresponding to PCT/EP2004/052389

Filed September 30, 2004]

THE COMMISSIONER IS AUTHORIZED TO CHARGE ANY DEFICIENCY IN THE FEE FOR THIS PAPER TO DEPOSIT ACCOUNT NO. 23-0975.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

1a.

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- [X] each U.S. Patent and U.S. Patent application publication;
 [] each reference previously cited in the international application PCT/______; and/or
 [] each reference previously cited in prior parent application Serial No.
 [X] This Information Disclosure Statement is submitted:
- within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

and thus no certification and/or fee is required.

1b. [] This Information Disclosure Statement is submitted

after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:

- (1) [] the certification of paragraph 2 below is provided, or
- (2) [] the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.
- 1c. [] This Information Disclosure Statement is submitted:

after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:

the certification of paragraph 2 below is provided, and

the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

2. It is hereby certified

- a. [] that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
- b. [] that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

- 3. [] Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
- 4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
 - a. [] a full or partial English language translation submitted herewith,
 - b. [X] a foreign patent office search report (International Search Report) (in the English language) of record,
 - c. [X] the concise explanation contained in the specification of the present application at page 1,
 - d. [] the concise explanation set forth in the attached English language abstract,
 - e. [] the concise explanation set forth below or on a separate sheet attached to the reference:
- 5. [X] A foreign patent office search report (International Search Report) citing one or more of the references is of record.

Respectfully submitted,

Peter HEROLD et al.

Registration No. 25,134

Attorney for Applicants

MRD/pth Washington, D.C. 20006-1021 Telephone (202) 721-8200 Facsimile (202) 721-8250 July 13, 2006

Sheet 1 of 2 INFORMATION DISCLOSURE STATEMENT										
FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE				ATTY DOCKET NO. SERIAL 2006_0446A 10/574						
PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S)				APPLICANT Peter HEROLD et al.						
(Use several sheets if necessary) Date Submitted to PTO: July 13, 2006				FILING DATE GROUP March 31, 2006						
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS		SUBCLASS	S FILING DATE IF APPROPRIATE	
/KH/	AA	6,051,712	4/2000	Bing	geli et al.					
000000000000000000000000000000000000000	АВ	6,150,526	11/2000	Bing	geli et al.					
200000000000000000000000000000000000000	AC	6,197,959	3/2001	Bre	eu et al.					
000000000	AD	2004/0204455	10/2004	Co	dy et al.					
000000000	AE	2002/0087002	7/2002	Bre	eu et al.				·····	
V	AF	6,376,672	4/2002	Bre	eu et al.					:
		<u> </u>	FORE	EIGN PATENT	DOCUMENTS	,		1		
		DOCUMENT NUMBER	DATE	COUNTRY CLASS S				SUBCLASS	TRANSLATION YES NO	
/KH/, ,	AG	97/09311	3/1997		WO					
000000000000000000000000000000000000000	АН	00/64887	11/2000		WO				- 4-14-	
000000000000000000000000000000000000000	AI	2004/002466	1/2004		wo		•			
30000000000	AJ	2004/089903	10/2004		wo			·		
V	AK	00/64873	11/2000		wo					
	,	OTHER	DOCUMENT(S)	Including Autho	or, Title, Date, Pertine	ent Pages	s, Etc.)			
/KH/	AL	Rolf Güller et al., "Piperidine-Renin Inhibitors Compounds with Improved Physicochemical Properties", Bioorganic & Medicinal Chemistry Letters, ISSN: 0960-894X, vol. 9, no. 10, pages 1403-1408, XP002317171, 1999.								
/KH/	AM	H.P. Märki et al., "Piperidine renin inhibitors: from leads to drug candidates", Farmaco, 56(1-2) ISSN: 0014-827X, pages 21-27, XP002317172, 2001.								
/KH/	AN	Daiga M. Helmeste et al., "Serotonin uptake inhibitors modulate intracellular Ca2+ mobilization in platelets", European Journal of Pharmacology, vol. 288, pages 373-377, XP002317173, 1995.								
/KH/	AO	Matthew G. Bursavich et al., "From Peptides to Non-Peptide Peptidomimetics: Design and Synthesis of New Piperidine Inhibitors of Aspartic Peptidases", Organic Letters, vol. 3, no. 15, pages 2317-2320, XP002317174, 2001.								
/KH/	AP	Matthew G. Bursavich et al., "Solid-Phase Synthesis of Aspartic Peptidase Inhibitors: 3-Alkoxy-4-Aryl Piperidines", Organic Letters, vol. 3, no. 17, pages 2625-2628, XP002317175, 2001.								
EXAMINER /Kahsay Habte/					DATE CONSIDERED 12/03/2008					

Sheet 2 of 2	,		INFORMA	TION DISCLO	SURE STATEMEN	T				
FORM PTO 1449 (modified)						SERIAL 10/574	RIAL NO. 574,108			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				APPLICANT Peter HEROLD et al.						
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Date Submitted to PTO: July 13, 2006				FILING DATE March 31, 2006			GROUP			
U.S. PATENT DOCUMENTS										
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	С	LASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	ВА									
·	ВВ									
	вс									
	BD									
	BE									
	BF									
	BG									
gerryttegs is	вн									
11 J.	ВІ									
			FORE	EIGN PATENT	DOCUMENTS					
		DOCUMENT NUMBER	DATE	C	OUNTRY	С	LASS	SUBCLASS	TRANSLATION YES NO	
· 	BJ								•	
	вк							·		
	BL									
	вм									
	BN		<u> </u>							
and the second	1	OTHER	DOCUMENT(S)	Including Author	or, Title, Date, Pertin	nent Page:	s, Etc.)		· .	
/KH/	во	Eric Vieira et al., "Substituted Piperidines - Highly Potent Renin Inhibitors Due to Induced Fit Adaptation of the Active Site", Bioorganic & Medicinal Chemistry Letters, vol. 9, pages 1397-1402, XP002317176, 1999.								
	BP									,
	BQ					<u>. </u>			. ;	
	10/09/2002									
EXAMINER /Kahsay Habte/				DATE CONSIDERED 12/03/2008						